Pay in 4 interest-free payments of $5.22 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
GLP-1 peptides work on pancreatic insulin signaling and gastric emptying
Glucose-dependent secretion
Empower compounded tirzepatide offers lower cost, dose flexibility, formulation options (injection and ODT), and the addition of niacinamide
TL;DR Victoza and Ozempic are GLP 1 receptor agonists manufactured by Novo Nordisk that treat type 2 diabetes and help control blood sugar levels Ozempic (semaglutide) is a once weekly injection that offers superior weight loss (approximately 13 lbs vs 4 lbs in 30 weeks) and better A1C reduction (-1.8% vs -1.2%) compared to Victoza (liraglutide) which requires daily injections Both medications work by mimicking the natural hormone GLP 1 to regulate blood glucose and reduce appetite Ozempic shows double the cardiovascular protection (26% vs 13% MACE reduction) Victoza is approved for children ages 10 and older while Ozempic is only approved for adults Ozempic pens are slightly more expensive per unit while Victoza pens are cheaper upfront but may run out faster due to daily dosing
Phase Mid escalation Weeks 9-12 Weekly Dose 6 mg Notes Watch GI
US$ 28.76
US$ 23.93
US$ 20.18
US$ 21.37
US$ 24.15
US$ 27.39
